Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 223-230

  Pogribny, Igor P ^a   Rusyn, Ivan ^b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b University of North Carolina   (United States)

Author keywords

DNA methylation; Hepatocellular carcinoma; Histone modifications; MicroRNAs

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE H3; HISTONE H4; MICRORNA;

CANCER GROWTH; CANCER MODEL; CANCER PROGNOSIS; CANCER RECURRENCE; CELL TRANSFORMATION; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE REPRESSION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MOLECULAR DIAGNOSIS; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; SHORT SURVEY;

EID: 84888198936     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.038     Document Type: Review

References (174)

1. Center M.M., Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol. Biomarkers Prev. 2011, 20:2362-2368.
2. E.P. Simard, E.M. Ward, R. Siegel, A. Jemal, Cancers with increasing incidence trends in the United States: 1999-through 2008, CA Cancer J. Clin., in press.
3. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002, 31:339-346.
4. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
5. Venook A.P., Papandreou C., Furuse J., de Guevara L.L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15:5-13.
6. Yang J.D., Roberts L.R. Epidemiology and management of hepatocellular carcinoma. Infect. Dis. Clin. North Am. 2010, 24:899-919.
7. Kremsdorf D., Soussan P., Paterlini-Brechot P., Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006, 25:3823-3833.
8. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25:3834-3847.
9. Sanyal A.J., Yoon S.K., Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010, 15:14-22.
10. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma. Cancer 2009, 115:5651-5661.
11. Wetzel T.M., Graubard B.I., Zeuzem S., El-Serag H., Davila J.A., McGlynn K.A. Metabolic syndrome increases risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
12. Hashimoto E., Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic?. Hepatol. Res. 2012, 42:1-14.
13. Libbrecht L., Desmet V., Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver. Int. 2005, 25:16-27.
14. Hussain S.P., Schwank J., Staib F., Wang X.W., Harris C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26:2166-2176.
15. Nault J.C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 2011, 31:173-187.
16. Nishida N., Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr. Genomics 2011, 12:130-137.
17. Calvisi D.F., Ladu S., Gorden A., Farina M., Lee J.S., Conner E.A., Schroeder I., Factor V.M., Thorgeirsson S.S. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 2007, 117:2713-2722.
18. Tischoff I., Tannapfe A. DNA methylation in hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1741-1748.
19. Herceg Z., Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat. Res. 2011, 727:55-61.
20. Harath N.I., Leggett B.A., MacDonald G.A. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 2006, 21:15-21.
21. Pogribny I.P., Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell. Mol. Life Sci. 2009, 66:2249-2261.
22. Mato J.M., Lu S.C. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 2007, 45:1306-1312.
23. Zeisel S.H. Genetic polymorphisms in methyl-group metabolism and epigenetic: lessons from humans and mouse models. Brain Res. 2008, 1237:5-11.
24. Ulrey C.L., Liu L., Andrews L.G., Tollefsbol T.O. The impact of metabolism on DNA methylation. Hum. Mol. Genet. 2005, 14:R139-R147.
25. Valinluck V., Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007, 67:946-950.
26. Chia N., Wang L., Senut M.C., Brenner C., Ruden D.M. Environmental regulation of 5-hydroxymethyl-cytosine by oxidative stress. Epigenetics 2011, 6:853-856.
27. Saito Y., Kanai Y., Nakagawa T., Sakamoto M., Saito H., Ishii H., Hirohashi S. Increased protein expression of DNA methyltransferase (DNMT1) is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int. J. Cancer 2003, 105:527-532.
28. Chen H., Li S., Diwan B.A., Barrett J.C., Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004, 25:1779-1786.
29. Mandrekar P. Epigenetic regulation in alcohol liver disease. World J. Gastroenterol. 2011, 28:2456-2464.
30. Ooi S.K., O'Donnell A.H., Bestor T.H. Mammalian cytosine methylation at a glance. J. Cell. Sci. 2009, 122:2787-2791.
31. Ooi S.K., Bestor T.H. The colorful history of active DNA demethylation. Cell 2008, 133:1145-1148.
32. Ma D.K., Guo J.U., Ming G.L., Song H. DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle 2009, 8:1526-1531.
33. He Y.F., Li B.Z., Li Z., Wang Y., Tang Q., Ding J., Jiz Y., Chen Z., Li L., Sun Y., Li X., Dai Q., Song C.X., Zhang K., He C., Xu G.L. Tet-mediated formation of 5-hydroxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
34. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1333.
35. Cortellino S., Xu J., Sannai M., Moore R., Caretti E., Cigliano A., Le Coz M., Devarajan K., Wessels A., Soprano D., Abramowitz L.K., Bartolomei M.S., Rambow F., Bassi M.R., Bruno T., Fanciulli M., Renner C., Klein-Szanto A.J., Matsumoto Y., Kobi D., Davidson I., Alberti C., Larue L., Bellacosa A. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146:67-79.
36. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
37. Lin C.H., Hsieh S.Y., Sheen I.S., Lee W.C., Chen T.C., Shyu W.C., Liaw Y.F. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001, 61:4238-4443.
38. Guerrero-Preston R., Santella R.M., Blanco A., Desai M., Berdasco M., Fraga M. Global DNA hypomethylation in liver cancer cases and controls: a phase I preclinical biomarker development study. Epigenetics 2007, 2:223-226.
39. De Smet C., Loriot A. DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics 2010, 5:206-213.
40. Takai D., Yagi Y., Habib N., Sugimura T., Ushijima T. Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn. J. Clin. Oncol. 2000, 30:306-309.
41. Kim M.J., White-Cross J.A., Shen L., Issa J.P., Rashid A. Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod. Pathol. 2009, 22:442-449.
42. Lee H.S., Kim B.H., Cho N.Y., Yoo E.J., Choi M., Shin S.H., Jang J.J., Suh K.S., Kim Y.S., Kang G.H. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15:812-820.
43. Tangkijvanich P., Hourpai N., Rattanatanyong P., Wisedopas N., Mahachai V., Mutirangura A. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin. Chim. Acta 2007, 379:127-133.
44. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H., Hirohashi S. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc. Natl. Acad. Sci. USA 2002, 99:10060-10065.
45. Wild L., Flanagan J.M. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim. Biophys. Acta 1806, 2010:50-57.
46. Wainfan E., Poirier L.A. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 1992, 52:2071s-2077s.
47. Christman J.K. Dietary effects on DNA methylation: do they account for hepatocarcinogenic properties of lipotrope diets?. Adv. Exp. Med. Biol. 1995, 369:141-154.
48. Pogribny I.P., James S.J., Jernigan S., Pogribna M. Genomic hypomethylation is specific for preneoplastic liver in folate/methyl deficient rats and does not occur in non-target tissues. Mutat. Res. 2004, 548:53-59.
49. Yamada Y., Jackson-Grusby L., Linhart H., Meissner A., Eden A., Lin H., Jaenisch R. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl. Acad. Sci. USA 2005, 102:13580-13585.
50. Tränkenschuh W., Puls F., Christgen M., Albat C., Heim A., Poczkaj J., Fleming P., Kreipe H., Lehmann U. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One 2010, 5:e13688.
51. Bagnyukova T.V., Tryndyak V.P., Montgomery B., Churchwell M.I., Karpf A.R., James S.R., Muskhelishvili L., Beland F.A. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008, 29:638-646.
52. Rollins R.A., Haghighi F., Edwards J.R., Das R., Zhang M.Q., Ju J., Bestor T.H. Large-scale structure of genomic methylation patterns. Genome Res. 2006, 16:157-163.
53. Maunakea A.K., Nagarajan R.P., Bilenky M., Ballinger T.J., D'Souza C., Fouse S.D., Johnson B.E., Hong C., Nielsen C., Zhao Y., Turecki G., Delaney A., Varhol R., Thiessen N., Shchors K., Heine V.M., Rowitch D.H., Xing X., Fiore C., Schillebeeckx M., Jones S.J.M., Haussler D., Marra M.A., Hirst M., Wang T., Costello J.F. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466:253-257.
54. Takai D., Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 2002, 99:3740-3745.
55. Illingworth R.S., Bird A.P. CpG islands - "a rough guide". FEBS Lett. 2009, 583:1713-1720.
56. Schagdarsurengin U., Wilkens L., Steinemann D., Flemming P., Kreipe H.H., Pfeifer G.P., Schlegelberger B., Dammann R. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003, 22:1866-1871.
57. INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin. Cancer Res. 2004, 10:7484-7489.
58. Harder J., Opitz O.G., Brabender J., Olschewski M., Blum H.E., Nomoto S., Usadel H. Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int. J. Cancer 2008, 122:2800-2804.
59. Roncalli M., Bianchi P., Bruni B., Laghi L., Destro A., Di Gioia S., Gennari L., Tommasini M., Malesci A., Coggi G. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated with hepatocellular carcinoma. Hepatology 2002, 36:427-432.
60. Edamoto Y., Hara A., Biernat W., Terracciano L., Cathomas G., Riehle H.M., Matsuda M., Fujii H., Scoazec J.Y., Ohgaki H. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 2003, 106:334-341.
61. Okochi O., Hibi K., Sakai M., Inoue S., Takeda S., Kaneko T., Nakao A. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin. Cancer Res. 2003, 9:5295-5298.
62. Miyoshi H., Fujie H., Moriya K., Shintani Y., Tsutsumi T., Makuuchi M., Kimura S., Koike K. Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma. J. Gastroenterol. 2004, 39:563-569.
63. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signaling in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
64. Yuan Y., Wang J., Li J., Wang L., Li M., Yang Z., Zhang C., Dai J.L. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin. Cancer Res. 2006, 12:6687-6695.
65. Zhong S., Tang M.W., Yeo W., Liu C., Lo Y.M., Johnson P.J. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin. Cancer Res. 2002, 8:1087-1092.
66. Tada M., Yokosuka O., Fukai K., Chiba T., Imazeki F., Tokuhisa T., Saisho H. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J. Hepatol. 2005, 42:511-519.
67. Shimoda M., Takahashi M., Yoshimoto T., Kono T., Ikai I., Kubo H. A homeobox protein, Prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin. Cancer Res. 2006, 12:6005-6011.
68. Laerm A., Helmbold P., Goldberg M., Dammann R., Holzhausen H.J., Ballhausen W.G. Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the biliary system. J. Hepatol. 2007, 46:89-97.
69. Macheiner D., Heller G., Kappel S., Bichler C., Stättner S., Ziegler B., Kandioler D., Wrba F., Schulte-Hermann R., Zöchbauer-Müller S., Grasl-Kraupp B. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J. Hepatol. 2006, 45:81-89.
70. Zhang C., Li H., Liu w., Zhang Q., Zhang T., Zhang X., Han B., Zhou G. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J. Hepatol. 2010, 53:889-895.
71. Olamura Y., Nomoto S., Kanda M., Hayashi M., Nishikawa Y., Fuji T., Sugimoto H., Takeda S., Nakao A. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann. Surg. Oncol. 2011, 18:572-579.
72. Kanda M., Nomoto S., Okamura Y., Hayashi M., Hishida M., Fujii T., Nishikawa Y., Sugimoto H., Takeda S., Nakao A. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol. Carcinog. 2011, 50:571-579.
73. Liu W., Li X., S Chu E., Go M.Y., Xu L., Zhao G., Li L., Dai N., SI J., Tao Q., Sung J.J., Yu J. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology 2011, 53:843-853.
74. Pogribny I.P., James S.J. Reduction of p53 expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett. 2002, 176:169-174.
75. Tomasi M.L., Li T.W., Mato J.M., Lu S.C. Inhibition of human methionine adenosyltransferase 1A transcription by coding region methylation. J. Cell. Physiol. 2012, 227:1583-1591.
76. Stefanska B., Huang J., Bhattacharyya B., Suderman M., Hallet M., Han Z.G., Szyf M. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 2011, 71:5891-5893.
77. Chan C.F., Yau T.O., Jin D.Y., Wong C.M., Fan S.T., Ng I.O. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin. Cancer Res. 2004, 10:4140-4149.
78. Xiao Y., Kleeff J., Shi X., Büchler M.W., Friess H. Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatol. Res. 2003, 26:192-198.
79. Zhao W., Liu H., Liu W., Wu Y., Chen W., Jiang B., Zhou Y., Xue R., Luo C., Wang L., Jiang J.D., Liu J. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int. J. Oncol. 2006, 28:1081-1088.
80. Okada H., Kimura M.T., Tan D., Fujiwara K., Igarashi J., Makuuchi M., Hui A.M., Tsurumaru M., Nagase H. Frequent trefoil factor 2 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int. J. Oncol. 2005, 26:369-377.
81. Yang H., Huang Z.Z., Zeng Z., Chen C., Selby R.R., Lu S.C. Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280:G184-G190.
82. Goel A., Mathupala S.P., Pedersen P.L. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J. Biol. Chem. 2003, 278:15240-15333.
83. Kong L.M., Liao C.G., Chen L., Yang H.S., Zhang S.H., Zhang Z., Bian H.J., Xing J.L., Chen Z.N. Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. J. Cell Mol. Med. 2011, 15:1415-1428.
84. Kitamura Y., Shirahata A., Sakuraba K., Goto T., Mizukami H., Saito M., Ishibashi K., Kigawa G., Nemoto H., Sanada Y., Hibi K. Aberrant methylation of the Vimentin gene in hepatocellular carcinoma. Anticancer Res. 2011, 31:1289-1291.
85. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
86. Zhai B., Yan H.X., Liu S.Q., Chen L., Wu M.C., Wang H.Y. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World J. Gastroenterol. 2008, 14:5665-5673.
87. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H., Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001, 33:561-568.
88. Oh K., Kim H., Park H.J., Shim Y.H., Choi J., Park C., Park Y.N. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int. J. Mol. Med. 2007, 20:65-73.
89. Fan H., Zhao Z.J., Cheng J., Su X.W., Wu Q.X., Shan Y.F. Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J. Gastroenterol. 2009, 15:2020-2026.
90. Kanai Y. Genome-wide DNA hypomethylation profiles in precancerous conditions and cancers. Cancer Sci. 2010, 101:36-45.
91. Jin B., Robertson K.D. DNA methylation: superior or subordinate in epigenetic hierarchy?. Genes Cancer 2011, 2:607-617.
92. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
93. Chiba T., Yokosuka O., Arai M., Tada M., Fukai K., Imazeki F., Kato M., Seki N., Saisho H. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J. Hepatol. 2004, 41:436-445.
94. Kondo Y., Shen L., Suzuki S., Kurokawa T., Masuko K., Tanaka Y., Kato H., Mizuno Y., Yokoe M., Sugauchi F., Hirashima N., Orito E., Osada H., Ueda R., Guo Y., Chen X., Issa J.P., Sekido Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res. 2007, 37:974-983.
95. Ya J.Y., Zhang L., Zhang X., He Z.Y., Ma Y., Hui L.J., Wang X., Hu Y.P. H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. J. Biol. Chem. 2010, 285:18828-18837.
96. Sistayanarain A., Tsuneyama K., Zheng H., Takahashi H., Nomoto K., Cheng C., Murai Y., Tanaka A., Takano Y. Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer. Res. 2006, 26:3585-3593.
97. Cai M.Y., Hou J.H., Rao H.L., Luo R.Z., Li M., Pei X.Q., Lin M.C., Guan X.Y., Kung H.F., Zeng Y.X., Xie D. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol. Med. 2011, 17:12-20.
98. Jiang G.L., Liu L., Buyse I.M., Simon D., Huang S. Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1. Int. J. Cancer 1999, 83:543-546.
99. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6:731-740.
100. Sudo T., Utsunomiya T., Mimori K., Nagahara H., Ogawa K., Inoue H., Wakiyama S., Fujita S., Shinouzu K., Mori M. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br. J. cancer 2005, 92:1754-1758.
101. Quint K., Agaimy A., Fazio P., Montalbano R., Steindorf C., Jung R., Hellerbrandt C., Hartmann A., Sitter H., Neureiter D., Ocker M. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 2011, 459:129-139.
102. Chen J., Zhang B., Wong N., Lo A.W., To K.F., Chan A.W., Ng M.H., Ho C.Y., Cheng S.H., Lai P.B., Yu J., Ng H.K., Ling M.T., Huang A.L., Cai X.F., Ko B.C. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011, 71:4138-4149.
103. Wu L.M., Yang Z., Zhou L., Zhang F., Xie H.Y., Feng X.W., Wu J., Zheng S.S. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010, 5:e14460.
104. Choi H.N., Bae J.S., Jamiyandorj U., Noh S.J., Park H.S., Jang K.Y., Chung M.J., Kang M.J., Lee D.G., Moon W.S. Expression and role of SIRT1 in hepatocellular carcinoma. Oncol. Rep. 2011, 26:503-510.
105. Apergis G.A., Crawford N., Ghosh D., Steppan C.M., Vorachek W.R., Wen P., Locker J. A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma. J. Biol. Chem. 1998, 273:2917-2925.
106. Cheng A.S., Lau S.S., Chen Y., Kondo Y., Li M.S., Feng H., Ching A.K., Cheung K.F., Wong H.K., Tong J.H., Jin H., Choy K.W., Yu J., To K.F., Wong N., Huang T.H., Sung J.J. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 2011, 71:4028-4039.
107. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., Bergman Y., Simon I., Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39:232-236.
108. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
109. Kim K.C., Geng L., Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 2003, 63:7619-7623.
110. Avila M.A., Berasain C., Torres L., Martin-Duce A., Corrales F.J., Yang H., Prieto J., Lu S.C., Caballería J., Rodés J., Mato J.M. Reduce mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J. Hepatol. 2000, 33:907-914.
111. Schröder P.C., Segura V., Riezu J.I., Sangro B., Mato J.M., Prieto J., Santamaría E., Corrales F.J. A signature of six genes highlights defects on cell growth and specific matabolic pathways in murine and human hetatocellular carcinoma. Funct. Integr. Genomics 2011, 11:419-429.
112. Corrales F.J., Pérez-Mato I., Sánchez Del Pino M.M., Ruiz F., Castro C., Garcia-Trevijano E.R., Latasa U., Martínez-Chantar M.L., Martínez-Cruz A., Avila M.A., Mato J.M. Regulation of mammalian liver methionine adenosyltransferase. J. Nutr. 2002, 132:2377S-2381S.
113. Burgio G., Onorati M.C., Corona D.F. Chromatin remodeling regulation by small molecules and metabolites. Biochim. Biophys. Acta 2010, 1799:671-680.
114. Teperino R., Schoonjans K., Aurwex J. Histone methyl transferases and demethylases; can they link metabolism and transcription. Cell Metab. 2010, 12:321-327.
115. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
116. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
117. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu. Rev. Med. 2009, 60:167-179.
118. Ventura A., Jacks S.T. MicroRNAs in cancer: short RNAs go a long way. Cell 2009, 136:586-591.
119. Di Leva G., Croce C.M. Roles of small miRNAs in tumor formation. Trends Mol. Med. 2010, 16:257-267.
120. Gramantieri L., Fornari F., Callegari E., Sabbioni S., Lanza G., Croce C.M., Bolondi L., Negrini M. MicroRNA involvement in hepatocellular carcinoma. J. Cell. Mol. Med. 2008, 12:2189-2204.
121. Mott J.L. MicroRNas involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology 2009, 50:630-637.
122. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
123. Connoly E., Melegari M., Landgraf P., Tchaikovskaya T., Tennant B.C., Slagle B.L., Rogler L.E., Zavolan M., Tuschl T., Rogler C.E. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 2008, 173:856-864.
124. Elyakim E., Sitbon E., Faerman A., Tabak S., Montia E., Belanis L., Dov A., Marcusson E.G., Bennett C.F., Chajut A., Cohen D., Yerushalmi N. Has-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010, 70:8077-8087.
125. Fornari F., Gramantieri L., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Giovannini C., Croce C.M., Bolondi L., Negrini M. Mir-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661.
126. Pineau P., Volinia S., McJunkin K., Marchio A., Battiston C., Terris B., Mazzaferro V., Lowe S.W., Croce C.M., Dejean A. MiR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA 2010, 107:264-269.
127. Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. Hepatology 2010, 52:1164-1166.
128. Wong Q.W., Ching A.K., Chan A.W., Choy K.W., To K.F., Lai P.B., Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin. Cancer Res. 2010, 16:867-875.
129. Tomimaru Y., Eguchi H., Nagano H., Wada H., Tomokuni A., Kobayashi S., Marubashi S., Takeda Y., Tanemura M., Umeshita K., Doki Y., Mori M. MicroRNA-21 induces resistance to the anti-tumor effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br. J. Cancer 2010, 103:1617-1626.
130. Fornari F., Gramantieri L., Giovannini C., Veronese A., Ferracin M., Sabbioni S., Calin G.A., Grazi G.L., Croce C.M., Tavolari S., Chieco P., Negrini M., Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009, 69:5761-5767.
131. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70:5184-5193.
132. He Y., Cui Y., Wang W., Gu J., Guo S., Ma K., Luo X. Hypomethylation of the has-miR-191 locus causes high expression of has-miR-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia 2011, 13:841-853.
133. Datta J., Kutay H., Nasser M.W., Nuovo G.J., Wang B., Majumder S., Liu C.G., Volinia S., Croce C.M., Schmittgen T.D., Choshal K., Jacob S.T. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68:5049-5058.
134. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. MiR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
135. Alpini G., Glaser S.S., Zhang J.P., Francis H., Han Y., Gong J., Stokes A., Francis T., Hughart N., Hubble L., Zhuang S.M., Meng F. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J. Hepatol. 2011, 55:1339-1345.
136. Braconi C., Kogure T., Valeri N., Huang N., Nuovo G., Costinean S., Negrini M., Miotto E., Croce C.M., Patel T. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011, 30:4750-4756.
137. Yuan J.H., Yang F., Chen B.F., Lu Z., Huo X.S., Zhou W.P., Wang F., Sun S.H. The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 2011, 54:2025-2035.
138. Huang J., Wang Y., Guo Y., Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70.
139. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., Cupta S., Moore J., Wrobel M.J., Lerner J., Reich M., Chan J.A., Glickman J.N., Ikeda K., Hashimoto M., Watanabe G., Daidone M.G., Roayaie S., Schwartz M., Thung S., Salvesen H.B., Gabriel S., Mazzaferro V., Bruix J., Friedman S.L., Kumada H., Llovet J.M., Golub T.R. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:1995-2004.
140. Villanueva A., Hoshida Y., Toffanin S., Lachenmayer A., Alsinet C., Savic R., Cornella H., Llovet J.M. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin. s{cyrillic}ancer Res. 2010, 16:4688-4694.
141. Villanueva A., Minguez B., Forner A., Reig M., Llovet J.M. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu. Rev. Med. 2010, 61:317-328.
142. Villanueva A., Hoshida Y., Battiston C., Tovar V., Sia D., Alsinet C., Cornella H., Liberzon A., Kobayashi M., Kumada H., Thug S.N., Bruix J., Newell P., April C., Fan J.B., Roayaie S., Mazzaferro V., Schwartz M.E., Llovet J.M. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011, 140:1501-1512.
143. Ammerpohl O., Pratschke J., Schafmayer C., Haake A., Faber W., von Kampen O., Brosch M., Sipos B., von Schönfels W., Balschun K., Röcken C., Arlt A., Schniewind B., Grauholm J., Kalthoff H., Neuhaus P., Stickel F., Schreiber S., Becker T., Siebert R., Hampe J. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int. J. Cancer 2012, 130:1319-1328.
144. Nagashio R., Aral E., Ojima H., Kosuge T., Kondo Y., Kanai Y. Carcinogenic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int. J. Cancer 2011, 129:1170-1179.
145. Hernandez-Vargas H., Lambert M.P., Le Calvez-Kelm F., Gouysse G., McKay-Chopin S., Tavtigian S.V., Scoazec J.Y., Herceg Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE 2010, 5:e9749.
146. Nishida N., Nagasaka T., Nishimura T., Ikai I., Boland C.R., Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008, 47:908-918.
147. Archer K.J., Mas V.R., Maluf D.G., Fisher R.A. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol. Genet. Genomics 2010, 283:341-349.
148. Um T.H., Kim H., Oh B.K., Kim M.S., Kim K.S., Jung G., Park Y.N. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J. Hepatol. 2011, 54:939-947.
149. Deng Y.B., Nagae G., Midorikawa Y., Yagi K., Tsutsumi S., Yamamoto S., Hasegawa K., Kokudo N., Aburatani H., Kaneda A. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 2010, 101:1501-1510.
150. Feng Q., Stern J.E., Hawes S.E., Lu H., Jiang M., Kiviat N.B. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp. Mol. Pathol. 2010, 88:287-292.
151. Lambert M.P., Paliwal A., Vaissière T., Chemin I., Zoulim F., Tommasino M., Hainaut P., Sylla B., Scoazec J.Y., Tost J., Herceg Z. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J. Hepatol. 2011, 54:705-715.
152. Lou C., Du Z., Yang B., Gao Y., Wang Y., Fang S. Aberrant DNA hypomethylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci 2009, 100:996-1004.
153. Formeister E.J., Tsuchiya M., Fujii H., Shpyleva S., Pogribny I.P., Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat. Res. 2010, 692:26-33.
154. Wong I.H., Lo Y.M., Zhang J., Ng M.H., Wong N., B/ Lai P., Lau W.Y., Hjelm N.M., Johnson P.J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer. Cancer Res. 1999, 59:71-73.
155. Yeo W., Wong N., Wong W.L., Lai P.B., Zhong S., Johnson P.J. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005, 25:266-272.
156. Wang J., Qin Y., Li B., Sun Z., Yang B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin. Biochem. 2006, 39:344-348.
157. Zhang Y.J., Wu H.C., Shen J., Ahsan H., Tsai W.Y., Yang H.I., Wang L.Y., Chen S.Y., Chen C.J., Santella R.M. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 2007, 13:2378-2384.
158. Tan S.H., Ida H., Lau Q.C., Goh B.C., Chieng W.S., Loh M., Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol. Rep. 2007, 18:1225-1230.
159. Chan K.C., Lai P.B., Mok T.S., Chan H.L., Ding C., Yeung S.W., Lo Y.M. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin. Chem. 2008, 54:1528-1536.
160. Sato F., Hatano E., Kitamura K., Myomoto A., Fujiwara T., Takizawa S., Tsuchiya S., Tsujimoto G., Uemoto S., Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria. PLoS ONME 2011, 6:e16435.
161. Li L.M., Hu Z.B., Zhou Z.X., Chen X., Liu F.Y., Zhang J.F., Shen H.B., Zhang C.Y., Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70:9798-9807.
162. Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., Huang L., Li H., Tan W., Wang C., Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011, 50:136-142.
163. Li J., Wang Y., Yu W., Chen J., Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem. Biophys. Res. Commun. 2011, 406:70-73.
164. Newell P., Villanueva A., Friedman S.L., Koike K., Llovet J.F. Experimental models of hepatocellular carcinoma. J. Hepatol. 2008, 48:858-879.
165. Heindryckx F., Colle I., Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int. J. Exp. Pathol. 2009, 90:367-386.
166. Fausto N., Campbell J.S. Mouse models of hepatocellular carcinoma. Semin. Liver Did. 2010, 30:87-98.
167. Hoenerhoff M.J., Pandiri A.R., Lahousse S.A., Hong H.H., Ton T.V., Masinde T., Auerbach S.S., Gerrish K., Bushel P.R., Shockley K.R., Peddada S.D., Sills R.C. Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice. similarities in the molecular landscape with human liver cancer. Toxicol. Pathol. 2011, 39:678-699.
168. Cabibbo G., Craxí A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2010, 14:255-352.
169. Pogribny I.P., James S.J., Beland F.A. Molecular alterations in hepatocarcinogenesis induced by dietary methyl deficiency. Mol. Nutr. Food Res. 2012, 56:116-125.
170. Kalari S., Pfeifer G.P. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv. Genet. 2010, 70:277-308.
171. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 2007, 40:142-150.
172. Utsunomiya T., Shimada M., Imura S., Morine Y., Ikemoto T., Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J. Gastroeterol. 2010, 45:146-152.
173. Tsuchiya M., Parker J.S., Kono H., Matsuda M., Fujii H., Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol. Cancer 2010, 9:74.
174. Utsunomiya T., Shimada M. Molecular characteristic of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol. Res. 2011, 41:711-721.